ArticleOncology letters2021
Circular RNA SLC26A4 regulates the maturation of microRNA-15a in non-small cell lung cancer cells.
Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circ_0020460 drives tumorigenesis in cervical cancer through miR-485-3p sponging.Discover oncology · 2024Article
- Identification of exosomal circSLC26A4 as a liquid biopsy marker for cervical cancer.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To the best of our knowledge, the oncogenic role of circular RNA solute carrier family 26 member 4 (circSLC26A4) has only been reported in cervical cancer, while its role in non-small cell lung cancer (NSCLC) is unknown. The present study explored the involvement of circSLC26A4 in NSCLC. NSCLC tissues and paired adjacent non-tumor tissues were collected from 64 patients with NSCLC. The expression levels of circSLC26A4, mature microRNA-15a (miR-15a) and miR-15a precursor in these tissues were determined by reverse transcription-quantitative PCR (RT-qPCR). NSCLC cells were transfected with pcDNA3.1-circSLC26A4 vector to overexpress circSLC26A4, followed by the measurement of the expression levels of mature miR-15a and miR-15a precursor using RT-qPCR. Cell proliferation was analyzed using a Cell Counting Kit-8 assay. circSLC26A4 expression was upregulated in NSCLC tissues, and its high expression was significantly associated with poor survival of patients with NSCLC. The expression levels of circSLC26A4 were correlated with the expression levels of mature miR-15a, but not the expression levels of miR-15a precursor in NSCLC tissues. In NSCLC cells, overexpression of circSLC26A4 was associated with downregulation of mature miR-15a expression, but not miR-15a precursor expression. A cell proliferation assay revealed that overexpression of circSLC26A4 reduced the inhibitory effects of overexpression of miR-15a on cell proliferation. Therefore, circSLC26A4 may suppress the maturation of miR-15a in NSCLC to inhibit cancer cell proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.